Independent family-owned group, DÔMES PHARMA has been active in the #pharmaceutical industry since 1947. It employs 400 people in France, the UK, Germany, Spain and the USA, and has consolidated sales of 90 million euros.

For over 70 years, the Group has been developing, manufacturing and marketing solutions for the health and well-being of pets. 3 complementary areas of expertise that cover the entire value chain of medicines and all distribution channels.

The French production site of the Dômes Pharma Group, Europhartech has been acting as a CMO (Contract Manufacturing Organization) for the human and veterinary pharmaceutical industry since 1992. Since 2023, the group has also had a production plant in the United States for the manufacture of its ophthalmology products.

Europhartech specialises in the development, transposition and industrial production of originator and generic drugs and nutraceuticals in dry form. It is also positioned in the small and medium production runs market.

Dômes Pharma’s commitment to CSR dates back to 2017. Since then, the context and the world have changed, which is why since 2021 the CSR approach has been integrated into the strategic plan. Referring to the triple bottom line “People, Planet, Profit”, our ambition is to CULTIVATE human capital, sustainable development and economic performance to develop our POSITIVE IMPACT.

The Dômes Pharma signature expresses this commitment.